📢 Exclusive on Gate Square — #PROVE Creative Contest# is Now Live!
CandyDrop × Succinct (PROVE) — Trade to share 200,000 PROVE 👉 https://www.gate.com/announcements/article/46469
Futures Lucky Draw Challenge: Guaranteed 1 PROVE Airdrop per User 👉 https://www.gate.com/announcements/article/46491
🎁 Endless creativity · Rewards keep coming — Post to share 300 PROVE!
📅 Event PeriodAugust 12, 2025, 04:00 – August 17, 2025, 16:00 UTC
📌 How to Participate
1.Publish original content on Gate Square related to PROVE or the above activities (minimum 100 words; any format: analysis, tutorial, creativ
Lianhuan Pharmaceutical: The LH-1801 project faces significant uncertainties at multiple critical stages from successful clinical trials to final market launch and profitability.
Jin10 data reported on July 8th that Lianhuan Pharmaceutical issued an announcement regarding abnormal fluctuations in stock trading. The LH-1801 project clinical trial adopts a non-inferiority design, and there is significant uncertainty regarding whether the target can ultimately be achieved. The LH-1801 project faces significant uncertainties in multiple key segments from successful clinical trials to final market launch and profitability. The LH-1801 project is currently still in the R&D stage and is expected to not have a significant impact on the company's operating income and performance for a considerable period of time.